Pancreatic cancer has a genetic component.
According to Cleary, the KRAS gene, which causes about half of all human cancers, is mutated in more than 90% of cases of pancreatic cancer. However, a medication to turn off this specific gene has not yet been developed. One of oncology's "holy grails" is figuring out how to successfully target KRAS with a drug, according to Cleary. A Nobel Prize could be given to whoever develops an efficient KRAS targeted therapy because it is so crucial to oncology.